Up in smoke? Boton makes pharma bet as vaping dream fades

A new acquisition is taking the e-cigarette maker back to its roots in chemically developed flavors and fragrances
Key Takeaways:
- Vaping products maker Boton will acquire 49% of an active pharmaceutical ingredient maker for 160 million yuan
- While larger peers like RLX and Smoore are turning to emerging markets with fewer rules, smaller players like Boton are getting squeezed out of the business
By Edith Terry
When brothers Wong Ming Bun and Wang Ming Fan listed their company, China Boton Group Co. Ltd. (3318.HK), on the Hong Kong Stock Exchange in 2005, it was called China Flavors and Fragrances, reflecting its business making flavors and fragrances for tobacco, food and consumer goods.
It made a major pivot in 2016, when it bought into the then-booming vaping business with its 750 million yuan ($113 million) acquisition of Kimree, an e-cigarette maker based in the city of Huizhou in South China’s Guangdong province. Kimree had sales in 200 countries and customers among the five top global tobacco brands. E-cigarette products quickly became Boton’s big breadwinner, contributing 52% of revenue in the first half of this year. In a nod to the business’ importance, the company changed its name to Boton, the brand name for its e-cigarette products, in 2020.
But as countries around the world tighten the screws on vaping, Boton appears to be taking a “back to the future”-style step with a new purchase announced last week. The deal will see it buy 49% of Shandong Ganghong Biotechnology, a maker of upstream ingredients used to make pharmaceuticals, pesticides and aromatic products, among other things.
Boton made its Kimree purchase during the heyday of China’s domestic vaping market. The domestic industry’s total sales peaked at 116 billion yuan in 2021, according to iiMedia. But new rules drove most manufacturers, retailers and customers out of the domestic market starting around mid-2022, with many brands looking for relief in less regulated overseas markets. Even overseas markets are clamping down recently, with Chinese e-cigarette exports falling from $110.8 billion in 2024 to $105.9 billion in 2025.
As a relatively small player in the industry, Boton appears to be taking a different path from larger peers like RLX (RLX.US) and Smoore International (0696.HK) by returning to its chemistry roots rather than expanding aggressively overseas. Its new move in that direction will see it pay 160 million yuan for the minority stake in Ganghong, an active pharmaceutical ingredient (API) maker. Boton said the deal strategically strengthens its core flavors and fragrances business. Ganghong has expertise in microchannel reactions, with 61 patents and a nationally accredited lab.
Investors unconvinced
Boton’s shares rose briefly after the announcement, but those gains quickly went up in smoke, like its vaping business is doing. At their current level around HK$3, the stock trades at less than a third of where it was at the peak of the vaping boom in 2021.
Investors haven’t completely given up on the company, awarding it a relatively respectable price to sales (P/S) ratio of 1.81. But even that is well below the 2.88 for RLX and 2.79 for Smoore, although all three companies have seen their shares bounce back considerably from recent lows when their prospects were more uncertain.
The Ganghong acquisition isn’t Boton’s first recent diversification move, reinforcing the impression that it’s moving away from the e-cigarette industry, or at least rebuilding its other revenue streams in food flavors and fine fragrances.
It also seems to be moving out of Shenzhen, the center of China’s huge vaping industry, which supplies 90% of the global market. In June, it paid another 240 million yuan for an industrial building in Shanghai to “facilitate future expansion” and provide an “alternative base,” it said. That came after it returned a plot of land to the Shenzhen government that it had leased for 50 years, receiving 2.7 billion yuan from the transaction.
The returned land included Boton’s headquarters since its founding in 1991, as well as its factory grounds, which reinforces the impression that it may be scaling back its e-cigarette business. Before 2000, the company provided business development services for flavor enhancers for traditional cigarettes, before building its own factory.
Boton hasn’t explicitly said it’s abandoning its vaping business, but pressure is increasing across the industry. In one of the latest tightening measures, China announced last month it would cancel the export tax rebate for vaping devices, effective next April 1. Before that, it cancelled its 13% value added tax rebate for exported nicotine-containing inhalation products in April this year.
Such rebates were once relatively common as Beijing sought to promote exports. But it has gradually scaled back or cancelled a growing number of those recently after Western governments complained they constituted a form of unfair state support.
Global clampdown
At the same time, both Europe and the U.S. have been adopting their own stricter rules on single-use e-cigarettes. The EU has also been discussing unified flavor control rules and regulating all nicotine products.
That storm of regulation has challenged Boton’s business for the last year and a half, since its e-cigarette and tobacco flavoring businesses make up three-quarters of its revenue. In 2025, its overall revenue decreased by 9.5% to 1.5 billion yuan. It plunged to a loss of more than 1 billion yuan for the year, largely due to an 845 million yuan goodwill impairment charge related its acquisition of four tobacco businesses.
For the year, revenue from the company’s tobacco flavors segment fell by 36.2%to 384.1 million yuan. Its other segments were relatively flat, with e-cigarette revenue growing by 4.6% year-over-year to 668.8 million yuan, and fragrances by 4.6% to 206 million yuan. Only the segment for food flavors showed slightly better growth, at 8.2% to 206 million yuan.
Things improved for the company this year, with overall revenue up by 25.3% year-on-year to 799 million yuan in the first half of 2026. The tobacco flavorings business continued to fall, shrinking 7.9% to 165 million yuan. E-cigarette products rebounded, rising 58.1% to 422 million yuan, though that was likely due to a rush to export products before the April 1 cancelation of the value added tax rebate. The company’s net income tumbled 75% to just 2.2 million yuan, dragged down by a falling gross margin and rising expenses.
There are other reasons why Boton might want to scale back its e-cigarette business. It has been in a long-running dispute with Kimree’s former owner, including allegations that 150 million yuan from the 2016 acquisition remained unpaid.
Over the longer term, Boton and its peers might take a lesson from global tobacco giant Philip Morris (PM.US), creator of the original Marlboro Man. The U.S. company was able to fend off health regulators by developing new products that it claims are less harmful than burning tobacco in traditional cigarettes, such “heat-not-burn” products that provide nicotine without creating actual smoke. The vaping industry has made similar claims that its products are less harmful than tobacco smoke, but regulators across the world don’t seem too convinced.
To subscribe to Bamboo Works weekly free newsletter, click here